Aura Biosciences, Inc. (AURA)
$6.27-4.13%Close
SELLRECOVERY · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $403M
- Beta
- 0.41
- P/E (TTM)
- -3.52
- Short % float
- 23.17%
- Days to cover
- 9.2
- SI change
- +47.0%
- 1W
- +1.62%
- 1M
- -10.56%
- vs SPY 1W
- +1.76%
- vs SPY 1M
- -13.06%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 14
- VALUE
- 8
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-43.9%
REV YoY-
ROE-73.2%
EPS YoY-
ROA-37.6%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-3.52
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.89
P/FCF-
EV/EBITDA-4.51
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E5.26
ALTMAN Z-
CURR RATIO16.82
ND/EBITDA-
BETA0.41
Company news
FAQ
- What is LOPJLB’s current signal on AURA?
- LOPJLB’s latest quantitative signal on Aura Biosciences, Inc. (AURA) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is AURA in?
- Aura Biosciences, Inc. (AURA) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Aura Biosciences, Inc. (AURA) do?
- Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-…